Seqens Seqens

X
[{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","amount":"$8.4 million","upfrontCash":"Undisclosed","newsHeadline":"Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by Revel Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic. Enzymes are applied therapeutically in only a handful of applications, including for wrinkle treatment (Botox), cancer (Asparaginase), and cystic fibrosis (DNase).

            Lead Product(s): Enzyme Therapy

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kizoo Technology Capital

            Deal Size: $8.4 million Upfront Cash: Undisclosed

            Deal Type: Financing March 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY